Latest News Archive

Please select Category, Year, and then Month to display items

Fighting COVID-19: Here is how we are helping

16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish

Farmovs — In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19.

The trial is expected to include more than 45 countries worldwide, including a number of South African sites.

Farmovs
FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients.

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe. FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.

News Archive

UFS cardiac team does pioneering work

2017-10-29

“With the use of endomyocardial biopsies, the team hopes to treat viruses unique
to Southern Africa, as well as other underlying causes of dilated cardiomyopathy.”

Photo: iStock

Members of the University of the Free State’s (UFS) Cardiac team had various achievements at national and international level this year. The Robert WM Frater Cardiovascular Research Centre in the Faculty of Health Sciences has commenced with a pioneering research project regarding idiopathic dilating cardiomyopathy.

With an Afrocentric research focus, Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS and Head of the Frater Centre, describes dilating cardiomyopathy as a heart muscle disease that is quite common, particularly among people of African descent. The disease weakens the heart muscle, which in turn leads to heart failure.

“To date there is no curable treatment for this condition, and 50% of patients who have shown heart failure, died within a period of five years. The causes of this condition have been unknown in the majority of patients. But over the past few years major strides have been made, where virus infections of the heart muscle, or myocarditis, have been identified as a possible underlying cause. Various genetic diseases are also linked to it,” says Prof Smit.

According to Prof Mokoali Makotoko, Head of the Department of Cardiology, more than 1 500 new cases of heart failure are identified at the Universitas Academic Hospital annually, of which approximately 30% are attributed to cardiomyopathy. “With the use of endomyocardial biopsies, the team hopes to treat viruses unique to Southern Africa, as well as other underlying causes of dilated cardiomyopathy.”

The study is a project that flows from Prof Makotoko’s PhD. The project is being run with Prof Heinz-Peter Schultheiss of the Charité University and the Institute for Cardiac Diagnostics and Therapy in Berlin, Germany.

"More than 1 500 new cases of heart failure are identified at the Universitas Academic Hospital annually, of which approximately 30% are attributed to cardiomyopathy."

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept